Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Antares Pharma to Present at the Roth 23rd Annual OC Growth Stock Conference

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer will present at the Roth 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 1:00 p.m. ET (Eastern Time).

A live webcast of the presentation will be available at http://www.wsw.com/webcast/roth24/ais/. The webcast will automatically be archived approximately three hours after the live event and will be available for 90 days.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, Valeo™/Vision™ reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd that includes Tev-Tropin® human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the Company's lead product candidate is Anturol®, an oxybutynin ATD™ gel that has completed Phase 3 studies for the treatment of OAB (overactive bladder). Antares also has a partnership with BioSante that includes LibiGel® (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.

Contacts:

Antares Pharma, Inc.
Robert F. Apple
Chief Financial Officer
609-359-3020
or
Investors:
Westwicke Partners, LLC
John Woolford
443-213-0506
john.woolford@westwicke.com
or
Media:
Tiberend Strategic Advisors, Inc.
Tamara Bright
212-827-0020
tbright@tiberendstrategicadvisors.com
or
Farrell Denby
fdenby@tiberendstrategicadvisors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.